INTS

INTENSITY THERAPEUTICS INC

• NASDAQ·07/17 15:05

  Intensity Resumes Phase 2 INVINCIBLE-4 Study For INT230-6 In Breast Cancer With Lower Dose

• TipRanks·07/15 11:50

  Intensity Therapeutics provides update in Invincicle-4 study

• Benzinga·07/15 11:48

  Intensity Therapeutics Administers New Patients With INT230‑6 In INVINCIBLE‑4 Switzerland Study; Trial Evaluates pCR Rates Vs Null Hypothesis Across SOC And INT230‑6+SOC Cohorts

• PUBT·07/15 11:45

  Intensity Therapeutics restarts Phase 2 INVINCIBLE-4 breast cancer trial, doses first patients in Switzerland

• Reuters·07/15 11:45

  INTENSITY THERAPEUTICS, INC. RESTARTS PATIENT TREATMENT IN THE RANDOMIZED, PRESURGICAL TRIPLE NEGATIVE BREAST CANCER PHASE 2 CLINICAL TRIAL (INVINCIBLE-4 STUDY)

• PUBT·07/01 12:07

  Intensity Therapeutics targets strategic partnerships to accelerate INT230-6 development

• PUBT·07/01 12:04

  Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trial

• Reuters·07/01 12:00

  INTENSITY THERAPEUTICS - OVER 200 PATIENTS ENROLLED IN COMPLETED INT230-6 STUDIES WITH PEER-REVIEWED PUBLICATION

• PR Newswire·07/01 12:00

  Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

• TipRanks·06/16 21:27

  Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting

• PUBT·06/16 20:15

  Intensity Therapeutics held annual shareholder meeting via webcast

• Seeking Alpha·05/08 10:25

  Intensity Therapeutics GAAP EPS of -$0.96

• Reuters·05/07 21:00

  Intensity Therapeutics Q1 net loss narrows on lower R&D costs

• Reuters·05/07 20:06

  INTENSITY THERAPEUTICS Q1 BASIC EPS USD -0.96

• PR Newswire·04/15 13:15

  Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation